A de-escalating dose study of the anti-VEGF agent, bevacizumab, reported efficacy at inhibiting severe ROP in the short-term using 1/20th the dose originally reported in the Bevacizumab Eliminates the Angiogenic Threat (BEAT)-ROP study [8, 9]; however, serum VEGF was still reduced at this dose at 1 month. This evidence concerns the gene VEGFA and retinopathy of prematurity.